Key terms
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest REPL news
Apr 07
5:39pm ET
Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy
Apr 04
8:16am ET
Replimune Group announces inducement grants under Nasdaq listing rule
Mar 26
7:42am ET
Replimune Group Announces Major Executive Team Overhaul
Feb 15
6:26am ET
Positive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials
Feb 15
6:15am ET
Replimune Group price target raised to $12 from $10 at H.C. Wainwright
Feb 13
5:50am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 09
7:31am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 09
3:40am ET
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
Feb 09
1:00am ET
Replimune Group Is Worried About This – Should You Be Worried Too?
Feb 08
8:02am ET
Replimune Group announce cash runway extended
Feb 08
8:02am ET
Replimune Group reports Q3 EPS (77c), consensus (93c)
Feb 07
8:05am ET
Disc Medicine appoints Franchi as CFO
Jan 09
9:25am ET
BMO Capital Keeps Their Buy Rating on Replimune Group (REPL)
No recent press releases are available for REPL
REPL Financials
Key terms
Ad Feedback
REPL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
REPL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
